sales@fusionmarketresearch.com + (210) 775-2636 (USA)

Healthcare and Pharmaceuticals


Research Reports

(COVID-19 Version) Global Small Molecule API Market Status (2015-2019) and Forecast (2020-2025) by Region, Product Type & End-Use

October 2020

Summary The report forecast global Small Molecule API market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation. The report offers detailed coverage of Small Molecule API industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Small Molecule API by geography. The report splits the market size, by volume and value, on the basis of application type and geography. First, this report covers the present status and the future prospects of the global Small Molecule API market for 2015-2024. And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]. At the same time, we classify Small Molecule API according to the type, application by geography. More importantly, the report includes major countries market based on the type and application. Finally, the report provides detailed profile and data information analysis of leading Small Molecule API company. Key Content of Chapters as follows (Including and can be customized) : Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Company information, Sales, Cost, Margin etc. Part 3: Global Market by company, Type, Application & Geography Part 4: Asia-Pacific Market by Type, Application & Geography Part 5: Europe Market by Type, Application & Geography Part 6: North America Market by Type, Application & Geography Part 7: South America Market by Type, Application & Geography Part 8: Middle East & Africa Market by Type, Application & Geography Part 9: Market Features Part 10: Investment Opportunity Part 11: Conclusion Market Segment as follows: By Region Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia] Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland] North America[United States, Canada, Mexico] Middle East & Africa[GCC, North Africa, South Africa] South America[Brazil, Argentina, Columbia, Chile, Peru] Key Companies Johnson-Matthey Cambrex Carbogen-Amcis Novasep Fareva Patheon AMRI Almac CordenPharma Albemarle Corporation Merck Market by Type Synthetic & Chemical API Biological API Market by Application Cardiovascular Tumor Diabetes Immune Diseases


(COVID-19 Version) Global Smokeless Tobacco Treatment Market Status (2015-2019) and Forecast (2020-2025) by Region, Product Type & End-Use

October 2020

Summary The report forecast global Smokeless Tobacco Treatment market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation. The report offers detailed coverage of Smokeless Tobacco Treatment industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Smokeless Tobacco Treatment by geography. The report splits the market size, by volume and value, on the basis of application type and geography. First, this report covers the present status and the future prospects of the global Smokeless Tobacco Treatment market for 2015-2024. And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]. At the same time, we classify Smokeless Tobacco Treatment according to the type, application by geography. More importantly, the report includes major countries market based on the type and application. Finally, the report provides detailed profile and data information analysis of leading Smokeless Tobacco Treatment company. Key Content of Chapters as follows (Including and can be customized) : Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Company information, Sales, Cost, Margin etc. Part 3: Global Market by company, Type, Application & Geography Part 4: Asia-Pacific Market by Type, Application & Geography Part 5: Europe Market by Type, Application & Geography Part 6: North America Market by Type, Application & Geography Part 7: South America Market by Type, Application & Geography Part 8: Middle East & Africa Market by Type, Application & Geography Part 9: Market Features Part 10: Investment Opportunity Part 11: Conclusion Market Segment as follows: By Region Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia] Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland] North America[United States, Canada, Mexico] Middle East & Africa[GCC, North Africa, South Africa] South America[Brazil, Argentina, Columbia, Chile, Peru] Key Companies  Pfizer Inc. GlaxoSmithKline plc. Johnson & Johnson Services Inc. Novartis Cigna Yesmoke Habitrol Perrigo Co. Plc. Cambrex Corporation Fertin Pharma Veracyte, Inc. Market by Type Chewing Tobacco Snuff/Dipping Tobacco Dissolvable Tobacco Market by Application Hospitals & Clinics Academic & Research Organizations Pharmacies


Non-Invasive Prenatal Testing (NIPT) Market (Panorama, Bambni Test, Harmony, MaterniT21 PLUS, NIFTY, PrenaTest, Verifi, VisibiliT, informaSeq, Veracity, IONA Test) - Global Market Analysis, Size, Volume, Share, Growth, Trends and Forecast 2011 – 2021

March 2020

Non-Invasive Prenatal Test (NIPT) are targeted at the detection of certain specific chromosomal aneuploidies from maternal blood sample in pregnant women at high risk for fetal aneuploidies. Currently, the prenatal testing market is experiencing a paradigm shift from conventional prenatal screening and diagnostic methods to non-invasive prenatal testing. This is mainly because of the advantages associated with NIPTs such as safety, accuracy, and no risk of miscarriage during the genetic screening test for common chromosomal abnormalities. NIPT is one of the most promising new areas of screening because it delivers highly actionable insights for empowering critical health decisions. The global non-invasive prenatal testing market is segmented on the basis of tests viz; Harmony, MaterniT21 PLUS, PrenaTest, Verifi, BambniTest, Panorama, InformaSeq, Non-Invasive Fetal Trisomy Test (NIFTY), VisibiliT, Veracity and IONA Test. NIPT has experienced substantial growth over the past few years. MaterniT21 plus test has gain its momentum in 2011 when there was only one NIPT test available in the market. In 2015, The MaterniT21 plus test market revenue decreased with XXX% compared to 2014. MaterniT21 test market revenue value was US$ XXX Million in 2015. Natera has emerged as one of the leading companies, with innovative technologies and a strong commercial base. Natera Panorama test will lead the NIPT market in the forecasting period with the market share of XXX% by the year 2021. Other NIPT tests such as Harmony, Verifi and NIFTY have emerged as the promising test in the NIPT test market. The major companies are expanding their tests through Collaboration, Distribution Agreement, Strategic Alliances and Partnerships with Clinical Laboratories and Hospitals. DPI Research report titled Non-Invasive Prenatal Testing (NIPT) Market (Panorama, Bambni Test, Harmony, MaterniT21 PLUS, NIFTY, PrenaTest, Verifi, VisibiliT, informaSeq, Veracity, IONA Test) - Global Market Analysis, Size, Volume, Share, Growth, Trends and Forecast 2011 – 2021. The report presents a comprehensive study of the Global NIPT market with market revenue and volume of the tests. market shares for leading NIPT test, comparative analysis of the non–invasive prenatal testing, NIPT implementation in HICs and LMICs, major deals in the NIPT market such as Collaborations, Partnerships, Distribution Agreement, Venture Capital Investment, Merger & Acquisition, Licensing Agreement and Exclusive Agreement. The report also covers market growth drivers, challenges, current and upcoming trends of the NIPT test market Key segments of the Global NIPT market The 11 NIPT Test covered in the report has been analyzed from 2 viewpoints: 1. NIPT Test Market Revenue (2011 - 2021) 2. NIPT Test Volume (2011 - 2021) The following are the NIPT test name which is covered in the report. 1) BambniTest 2) Harmony 3) informaSeq 4) MaterniT21 PLUS 5) NIFTY 6) Panorama 7) PrenaTest 8) verifi 9) VisibiliT 10) Veracity 11) IONA Test The report also covers NIPT implementation in High Income Countries and Low - or- Middle Income Countries. The 3 issues for implementation covered are: 1) Clinical Issues 2) Ethical Issues 3) Legal and Regulatory Issues This report gives access to significant data such as: • Market Growth Drivers • Challenges in the NIPT Test Market • Current Market Trends • Market Forecasting for the Coming Years • Comparative Test Analysis Data Sources The information contained in this report is based on both primary and secondary sources. Primary Sources: Questionnaires, Surveys, telephonic interviews with industry experts and Observations Secondary Sources: Secondary data analysis and review involves collecting and analysing a vast array of information. DPI Research seeks information from different sources such as published articles, company websites, magazine articles, associations, trade journals, annual reports, Newspapers, Books, Government official websites and other paid database sources.


Point of Care Testing – Global Analysis & Market Forecasts

March 2020

Point of care (POC) technologies are rapidly becoming part of the revolution of the healthcare landscape. With evolving high–tech innovations in healthcare, including smartphone apps, biosensors, lab–on–a chip, and wearable devices—all of which offer a closer connection to the patient. The dynamic of point of–care testing (POCT) is to bring testing closer to the patient and results conveniently and quickly to the provider to expedite diagnosis and subsequent treatment. POCT allows for faster clinical decisions in hospitals, physicians’ offices, ambulances, patient homes, and in the field. The global point of care testing market is projected to reach US$ 38 Billion by 2022, at a CAGR of XX% from 2016 to 2022. The global market is mainly driven by increasing prevalence of infectious diseases in developing countries, the rising incidences of lifestyle diseases such as cardiac diseases and diabetes, the rising usage of home–based POC devices, and technological advancements with regard to development of advanced, faster, and easy to–use devices are stimulating the demand for POCT This report titled “Point of Care Testing – Global Analysis & Market Forecasts” provides a comprehensive analysis of the emerging point of care tests market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report also provides market landscape and market share information in the point of care testing market. The report brings together major merger & acquisition, distribution agreement, licensing deals and collaboration deals information in point of care testing market. The report also entails major drivers and challenges of point of care testing market. The following 13 segments of the point of care testing market are detailed with market size and six year forecast. • Blood Glucose Testing • Cardiac Markers Testing • Lipid Panel/Cholesterol Testing • Blood Coagulation Testing • Infectious Disease Testing • Urinalysis Testing • Drug of Abuse Testing • Pregnancy & Fertility Testing • Cancer Markers Testing • Critical Care Testing • HbA1C Testing • Clinical Chemistry Testing • Bilirubin Testing This report also gives access to significant data such as: • Market Growth Drivers in the Point of Care Testing Market • Challenges in the Point of Care Testing Market • Current Market Trends • Market Forecasting for the Coming Years • Merger & Acquisitions between major companies • Distribution Agreement • Licensing Deals • Collaboration Deals


Molecular Diagnostics Market – Global Industry Analysis, Size, Share, Growth Trends & Forecast to 2021

March 2020

Molecular Diagnostics has emerged as one of the largest and fastest growing segment in the IVD industry. It is the most dynamic and transformative areas of diagnostics, leading to advances in research and treatment that are revolutionizing healthcare across a wide range of diseases and health conditions and has been driven by accuracy, high sensitivity, fast turnaround time, easy workflow, and cost–effective testing. The global molecular diagnostics market is projected to reach more than US$ 30 Billion by 2021, at a CAGR of XX% from 2016 to 2021.The global market is mainly driven by chronic infections, growing geriatric population, increasing demand for personalized medicines, and R&D activities for biomarker identification equipped with emergence of new technology and applications. In addition, innovations in molecular diagnostics for treating cancer, government support for research and development, and high patient awareness levels are driving the growth of molecular diagnostic market North America dominates the global market of molecular diagnostics due to increasing incidence of infectious diseases and lifestyle associated diseases. North America controls more than 40% of the market share by the year 2021. Japan, China and India is expected to show high growth rates in the next six years in molecular diagnostics market. On the basis of application, Molecular oncology tests have emerged as a significant rapidly growing market segment. Oncology test controls nearly 25% market share by the year 2021. Other segments such as infectious diseases test and genetic testing is poised to be remarkable expansion in the near future. Growing demand for infectious diseases and genetic tests is an opportunity for global molecular diagnostics market. In terms of technology, Biochips/Microarrays is the fastest growing segment and is expected to boom further within the forecast period. FISH & Innovations and PCR based test is expected to grow at the highest CAGR in the coming years. On the basis of company, Roche is the leading company with more than 30% market share in the global molecular diagnostics market and is expected to hold its strong position in the market. Becton Dickinson, Myriad Genetics, Abbott and Qiagen is expected to robust market growth in the global molecular diagnostics market. The Research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically–supported and industry–validated market data and projections with a suitable set of assumptions and methodology. It provides analysis and information by categories such as 1) Market and Forecast 2) Application Wise Market & Forecast 3) Geographical Market & Forecast 4) Technology Wise Market & Forecast 5) Company Wise Molecular Diagnostics Sales & Forecast 6) Market Growth Drivers & Challenges Global Molecular Diagnostics Market has been analyzed from 6 viewpoints: 1) Market and Forecast 2) Application Wise Market & Forecast 3) Geographical Market & Forecast 4) Technology Wise Market & Forecast 5) Company Wise Molecular Diagnostics sales & Forecast 6) Market Growth Drivers & Challenges The following application segments of the molecular diagnostics market are detailed with size and six year forecast. • Infectious Disease Testing • Cardiovascular Disease Testing • Oncology Testing • Neurological Disorders Testing • Food Pathogen Detection Testing • Genetic Testing • Blood Screening • Tissue Typing (HLA Testing) • Others Molecular Testing Furthermore, the following technology segments of the molecular diagnostics market are detailed with size and six year forecast. • PCR Based Test • PCR Related Technologies • Non–PCR Test • Fish & Innovations Testing • Biochips/Microarrays • Biosensors • Molecular Imaging • Other Technologies The report analyses the market based on regions and presents the forecast in terms of value for the next six years. Regions covered in the report include: • North America • Europe • Japan • China • India • Brazil • Mexico • Korea • Rest of the world The following companies of the molecular diagnostics market are detailed with size and six year forecast. • Roche • Abbott Laboratories • Myriad Genetics • Qiagen • Cephied • Becton Dickinson • Biomerieux • Other Companies Research You Can Trust: This reports are written by our research team, a dedicated group of analysts that knows the industry inside and out. Data Sources The information contained in this report is based on secondary sources. Secondary Sources: Secondary data analysis and review involves collecting and analysing a vast array of information. Research team seeks information from different sources such as published articles, company websites, magazine articles, associations, trade journals, annual reports, newspapers, books, Government official websites and other paid database sources.


China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021

March 2020

The in–vitro diagnostics(IVD) market in China has been growing rapidly in the past few years and is expected to grow steadily in the next few years, with major growth potential in segments such as infectious disease testing, chronic disease testing and diagnosis in early stages of disease. Some of the major factors driving the growth of this market are the rising incidences of chronic lifestyle diseases, public health awareness, growing aging population, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for high–end products and an increase in the number of private hospitals and independent testing laboratories. However, low reimbursement rate, absence of quality products by the local companies, population factors and foreign companies faces difficulty to enter the low end IVD products market are restraining the growth of this market. Long–term Outlook: The China In Vitro Diagnostics Market is expected to reach more than US$ 10 Billion by 2021 with strong double digit growth rate from 2016 to 2021. China IVD Market: Segment wise Outlook Immunoassay has emerged as a significant rapidly growing market segment in China IVD market. Immunoassay test controls nearly XX% market share by the year 2021. Other segments such as Clinical Chemistry, Molecular testing and POCT are poised to be remarkable expansion in the near future. Growing demand for infectious disease testing, chronic disease testing and diagnosis in early stages of disease will usher the China IVD market. China IVD Market: Companies wise Outlook Roche is the leading company with more than XX% market share in the China IVD market and is expected to hold its strong position in the market. Sysmex Corporation and Abbott Laboratories are the other top two players in the China IVD market. Mindray and Shanghai Kehua Bioengineering(KHB) are another major participant in this market with a good hold in clinical chemistry, immunoassay and molecular testing segments providing varieties of reagents nationwide and semi–auto and automatic biochemistry analyzers to low and mid–end market users. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market, market segments, company wise sales analysis, regulation, major distributors and laboratories of IVD and outlook of the Chinese IVD companies. This report titled “China In Vitro Diagnostics(IVD) – Opportunity Assessment, Competitive Landscape and Market Forecasts to 2021” has been analyzed from 10 viewpoints: 1. Market and Forecast (2010 – 2021) 2. Segment Wise Market and Forecast (2010 – 2021) 3. Company Wise IVD Sales and Forecast (2010 – 2021) 4. Regulation and its Latest Development 5. Future Prospects in Attractive In Vitro Diagnostics Segments 6. Regional Trends and Opportunities 7. Main Participants/Contributors 8. Major IVD Product Companies Outlook 9. Major Private Clinical Labs and Diagnostic Services Companies Outlook 10. Market Growth Drivers and Challenges The following segments of the China In Vitro Diagnostics market are detailed with size and six year forecast. ? Clinical Chemistry ? Immunoassay ? Molecular Testing ? Self–Monitoring of Blood Glucose (SMBG) ? Point of Care Testing (POCT) ? Hematology ? Coagulation ? Microbiology The following companies of the China In Vitro Diagnostics market are detailed with size and six year forecast ? Roche Diagnostics ? Abbott Laboratories ? Mindray Medical International Limited ? Sysmex Corporation ? Shanghai Kehua Bio–Engineering Co. Ltd. ? Other Companies The following Chinese companies of the China In Vitro Diagnostics market are detailed with company overview and its product portfolio ? Mindray Medical International Limited ? Shanghai Fosun Pharmaceutical Group ? Mingyuan Medicare ? Da An Gene Co. Ltd. ? Shanghai Kehua Bio–Engineering Co. Ltd. ? Zhejiang D.a. Diagnostics Technology Co., Ltd ? ADICON Clinical Laboratories ? Guangzhou Kingmed Diagnostics Center Co. Ltd. ? Kindstar Global ? BGI – Shenzhen ? OriGene Technologies


Non-Invasive Prenatal Testing Market(NIPT) by Country (Actual and Potential), Test Outlook, Deals Type, Growth, Share, Opportunities and Forecast to 2021

March 2020

The global NIPT test market accounted for US$ XX Million in 2015 and is expected to reach US$ XX Million in 2016 and US$ XX Million by 2021, growing at a CAGR of XX% during the forecast period. Market growth can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). With increased patient access to NIPT test, the NIPT market is anticipated to have a positive outlook in the coming years. High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of NIPT test market. United States is seen as the dominant player in the NIPT test market followed by Germany, China and India in 2015. In the coming years, NIPT test market is expected to witness the highest growth rate in the Asian region, with emphasis on China and India. These countries are expected to increase revenues for the manufacturers of tests involved in NIPT test market. On the basis of test, MaterniT21 plus test has gain its momentum in 2011 when there was only one NIPT test available in the market. MaterniT21 test market revenue value was US$ XX Million in 2015. It is expected that MaterniT21 plus test will lead the NIPT test market with the market share of more than XX% by the year 2021. Other NIPT tests such as Panorama, Harmony, Verifi, NIFTY and Prerna test have emerged as the promising test in the NIPT test market. The major companies are expanding their tests through collaboration, distribution agreement, strategic alliances and partnerships with clinical laboratories and hospitals. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, country wise actual and potential market, NIPT test analysis with volume and market revenue and competitive landscape. The report also covers market growth drivers, challenges, current and upcoming trends of the NIPT test market GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION Global Non-Invasive Prenatal Testing (NIPT) Market – By Test Type 1. MaterniT21 PLUS 2. Harmony 3. NIFTY 4. Verifi 5. Panorama 6. PrenaTest 7. BambniTest 8. informaSeq 9. VisibiliT 10. Veracity 11. IONA Test Global Non-Invasive Prenatal Testing (NIPT) Market – By Country 1. United States 2. United Kingdom 3. Germany 4. Italy 5. Spain 6. France 7. Switzerland 8. Sweden 9. Belgium 10. Australia 11. New Zealand 12. Japan 13. China 14. India 15. Brazil


Kidney Transplant Market by Country (United States, Germany, France, Italy, United Kingdom, Japan, Argentina, Mexico, Spain, Brazil) Analysis and Forecast to 2021

March 2020

Kidney transplant is the most commonly conducted transplant surgery worldwide. It has gained widespread popularity by improving the outcome of end-stage renal disease (ESRD) patients. With advances in kidney transplant methods and improvement in transplant success, a kidney transplant is now widely considered to be the best way of treating chronic kidney disease for many people. As the number of organ donors is increasing, an increase in transplant procedures is bound to happen. However, due to costlier procedure the market shift is expected to occur in Asian countries where medical tourism is being promoted. Kidney Transplant Performed Analysis: United States is the leading kidney transplant performed with more than 40% share in 2015. The number of Kidney transplant done in 10 countries covered in the report was more than 40 Thousand in 2015. Brazil is the second leading kidney transplant performed country with more than 10% share. United Kingdom stands at the 3rd position in kidney transplant number. France and Mexico stand at the 4th and 5th place respectively in 2015. Kidney Transplant Market Analysis: United States is the leading market for kidney transplant in 10 countries covered being followed by France. Spain stands at the 3rd position followed by Germany. Japan and Italy are competing very closely with each other to capture the maximum market share. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides the number of kidney transplant, as well as market and market shares of Kidney Transplant market. The report entails major organ transplant (immunosuppressant) drug sales analysis. This report also covers key development, drivers and challenges of Kidney Transplant market. The 10 countries covered in the report are analysed from two viewpoints: 1. Number of Kidney Transplant Performed (2008 - 2021) 2. Kidney Transplant Market (2008 - 2021) Based on geographical distribution, the Kidney Transplant market is categorized into following sub-markets: 1. United States 2. Germany 3. France 4. Italy 5. United Kingdom 6. Japan 7. Argentina 8. Mexico 9. Spain 10. Brazil Organ Transplantation Immunosuppressive/Rejection Drugs Analysis in the report are as follows 1. Cellcept (Mycophenolate Mofetil) 2. Prograf(Tacrolimus) 3. Rapamune (Sirolimus) 4. Myfortic (Mycophenolic Acid) 5. Neoral / Sandimmune (Cyclosporine) 6. Zortress / Certican (Everolimus)


Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

March 2020

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants. The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period. Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market. Seven Major Markets(7MM) covered in the report are as follows: 1. United States 2. United Kingdom 3. France 4. Italy 5. Spain 6. Germany 7. Japan Major and Promising Vaccines covered in the report are as follows: 1. Fluzone High–Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN–100 11. M–001 12. VAX–2012Q 13. TAK – 850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Seasonal Influenza Vaccine Report is segmented with 10 Chapters: Chapter 1: Chapter one is the introduction with Executive Summary Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts 1. Overall seasonal influenza vaccine market data from 2010 to 2022 2. Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022 3. Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022 4. Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022 Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market. Chapter 4: Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage. Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination. Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan. Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals. Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines. Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase. Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.


United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

March 2020

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market. Major and Promising Vaccine covered in the report are as follows: 1. Fluzone High–Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN–100 11. M–001 12. VAX–2012Q 13. TAK – 850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Key Companies Covered in the Report are as follows 1. Sanofi Pasteur 2. GlaxoSmithKline(GSK) 3. Seqirus 4. AstraZenecca 5. Protein Sciences Corporation 6. Novavax 7. Daiichi–Sankyo 8. Mitsubishi Tanabe Pharma 9. BiondVax Pharmaceuticals Ltd 10. VaxInnate


Page : 384



Contact Us

Address

Pride Icon, Office No - 709,Thite Nagar, Kharadi,Pune, Maharashtra, India 411014

Phone Number

+(210) 775-2636